Inimmune is emblematic of the type of startup success story that is becoming transformational for Montana’s economy. In addition to proving highly adept at securing federal funds to support their research targets, commercialization efforts, and high-paying jobs to execute on these fronts, in 2020, Inimmune secured the largest Series A round in Montana history with a $22 million commitment from Two Bear Capital.
Missoula based Inimmune Corporation was named the Montana Ambassadors Business of the
Year in an announcement this week by Governor Gianforte. This award is presented annually to a
Montana business that “has demonstrated extraordinary innovation and success in their field of
Inimmune, is emblematic of the type of startup success story that is transforming Montana’s economy .
Montana Career Opportunities – Investigator (I or II) in Pharmaceutical & Formulation Science, Postdoctoral Formulations Scientist – Inimmune
The Inimmune team of scientific professionals is a group of good-natured, hardworking, fun-loving, innovative problem solvers that strive to deliver superior immunotherapeutics to improve the quality of life for all humankind.
The company has partnered with the University of Montana to advance basic research discoveries into
medicines and train a new workforce for Montana’s growing biotech sector. In 2020, Inimmune
secured one of the largest Series A investment rounds in Montana history with a $22 million
commitment from Two Bear Capital, (Whitefish, MT).
When the Series A investment was announced last July, Dr. Jay Evans, Inimmune’s CEO, noted that the company
“could have looked outside of Montana for investors but were happy to find a local VC firm (Two
Bear Capital) that connected with our vision to grow a world–class biotech company right here in
Montana.” (The Rise of Venture Capital in Montana, Flathead Beacon, Feb 24, 2021).
Founded in 2016, Inimmune develops vaccines and immunotherapeutics in areas of high unmet
medical need to communities across Montana and the country. Inimmune is advancing treatments
for allergy, oncology, autoimmunity, infectious disease and opioid addiction with several lead
candidates moving to Phase I human clinical trials in 2022. “Being located in Montana is a key to
our success,” said Dr. Evans, “Many of our employees are graduates of Montana colleges or have
a strong connection to the community. This strong sense of community and desire to help others
keeps our team focused on innovation and developing the next generation of immunotherapeutics.”
Montana Ambassador Award recipients announced by Governor Gianforte. Check out the full list of recipients, including Inimmune.